Alimera Sciences (ALIM) Misses Q1 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Alimera Sciences Announces First Quarter 2016 Financial Results
May 4, 2016 4:23 PM EDTFirst quarter revenue improved 49% compared to first quarter 2015 due to increasing ILUVIEN® sales in the U.S.Record benefit investigations in the first quarter indicate increasing physician demandOver 5,000 eyes treated with ILUVIEN® in four primary marketsAlimera to host conference call on May 5, 2016 at 10:00 AM ET
ATLANTA, May 04, 2016 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of... More
